Syndax Pharmaceuticals, Inc.

Public Equity (NASDAQ)BiopharmaceuticalOncologyPublic

📍 New York, NY, USA

StreetZero Signal 56

Be the first to signal interest

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted therapies for cancer. Its pipeline includes menin inhibitors such as revumenib and the anti-CSF-1R antibody axatilimab. The company is publicly listed on NASDAQ under the ticker SNDX.

LATEST FUNDINGRule 144

$115K

Announced 2026-10-29

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Syndax Pharmaceuticals, Inc..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

EMPLOYEES—

FOUNDED—

HQNew York, NY, USA

Industry

Public Equity (NASDAQ)

Investors

Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.

Key highlights

Completed $114,560 Rule 144 transaction
Publicly traded on NASDAQ (SNDX)
Develops targeted oncology therapies including menin inhibitors

Ask StreetZero about Syndax Pharmaceuticals, Inc.

Put our AI to work on this deal.

What is Syndax Pharmaceuticals, Inc.'s value proposition?Who are Syndax Pharmaceuticals, Inc.'s competitors?Why does this raise matter?Summarize Syndax Pharmaceuticals, Inc. for an investor.

Similar companies

Other Public Equity (NASDAQ) deals, ranked by Signal.

Crowdstrike Holdings, Inc.

$141.0M

Paylocity Holding Corporation

$66.0M

BENTLEY SYSTEMS INC

$67.5M

Palo Alto Networks Inc

$201.4M

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.